Antibody Engineering:

Richard H.J. Begent, M.D., Head of Oncology, Ronald Raven Professor of Oncology, University College London, United Kingdom

Andrew Bradbury, M.B., B.S., Ph.D., Research Scientist, Los Alamos National Laboratories

Dennis R. Burton, Ph.D., Professor, Immunology Department, The Scripps Research Institute

James S. Huston, Ph.D., Vice President & Senior ResearchFellow, EMD Serono Research Center

James D. Marks M.D., Ph.D. Professor of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco

Andreas Plückthun, Ph.D., Professor of Biochemistry, Department of Biochemistry, University of Zürich, Switzerland

Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry, Simon Fraser University, Canada

Ian M. Tomlinson, Ph.D., Senior Vice President, Biopharmaceuticals R & D, GlaxoSmithKline, United Kingdom

Louis M. Weiner, M.D., Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

Antibody Therapeutics

Rathin C. Das, Ph.D., Chief Business Officer, President, Affitech AS/ Affitech USA, Inc.

Mark R. Alfenito, Ph.D., President, KaloBios Pharmaceuticals Inc.

Benjamin P. Chen, Ph.D., Managing Director, Burrill & Company

Nils Lonberg, Ph.D., Senior Vice President and Scientific Director, Medarex Inc.

Trudi Veldman, Ph.D., Director, Biologics Generation, Abbott Laboratories